Carvolix SA (EPA:CVX)

Market Cap	199.06M +253.8%
Revenue (ttm)	900.00K -83.2%
Net Income	-24.97M
EPS	n/a
Shares Out	59.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,174
Open	3.280
Previous Close	3.280
Day's Range	3.280 - 3.600
52-Week Range	1.160 - 5.220
Beta	1.00
Analysts	Strong Buy
Price Target	4.93 (+46.73%)
Earnings Date	Jun 26, 2026

About Carvolix

Carvolix SA, a medical technology company, develops and markets minimally invasive minimally invasive medical devices in the field of urology and structural heart in France. It offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epygon implants for the treatment of mitral insufficiency, as well as Kardiozis technology for treating abdominal aortic aneurysm. The company was formerly known as Affluent Medical SA and changed its name to Carvolix SA in February 20...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2011
• Employees: 68
• Stock Exchange: Euronext Paris
• Ticker Symbol: CVX

Financial Performance

In 2025, Carvolix's revenue was 900,000, a decrease of -83.18% compared to the previous year's 5.35 million. Losses were -24.97 million, 69.4% more than in 2024.

Analyst Summary

According to 3 analysts, the average rating for CVX stock is "Strong Buy." The 12-month stock price target is €4.93, which is an increase of 46.73% from the latest price.

Price Target

€4.93

(46.73% upside)

Analyst Consensus: Strong Buy